Liver ADMET studies
D’Liver offers tailored in vivo liver uptake assays of biologics and nanopharmaceuticals, as well as general pharmacokinetic, biodistribution and liver cell toxicology studies. This includes biopharmaceutical compounds that are under development either as a free drug, drug formulation, or nanoparticle formulation. The assays can be performed in fish, mice, rats and pigs and will quickly determine whether a compound is taken up, distributed and/or metabolized by the liver.
We also offer general pharmacokinetic and biodistribution assays of native compound(s) or compound(s) labelled with isotopes/fluorochromes.
Liver cell distribution in vivo
With D’Liver’s specialised expertise in isolating highly purified freshly prepared cultures of hepatocytes, Kupffer cells (KCs) and liver sinusoidal endothelial cells (LSECs) we determine the exact cellular site(s) of liver uptake and metabolism after administration of the compound. We also detect toxicological effects on these cell types. The assays can be performed in fish, mice, rats and pigs.
The major cell type responsible for liver metabolism of biopharmaceutical compounds are most often not hepatocytes, but the lesser known liver sinusoidal endothelial cells (LSECs). Consequently, any liver metabolism studies need to include the LSEC in order to reveal the complete interaction of biopharmaceuticals with liver cells.
- Pharmacokinetic and bioavailability assays in various animal models, eg. fish, mice, rats and pigs
- Labelling of compound(s) with radioisotopes and/or fluorochromes
Key benefits and features
- Thorough analysis of biodistribution
- Results reflect the corresponding events in humans
- Analyse native compounds or compounds labelled with 3H, 13C, 14C, 15N, 18F, 125I and/or fluorochromes
- Studies tailored to our customers’ specific requirements
- Swift response to requests
- Quality in execution and delivery